Deciphering stringent response proteins and toxin-antitoxin systems in the arms race between bacteria and phages

This project aims to identify phage proteins that target bacterial defense systems to advance phage therapy and improve bioremediation by studying Pseudomonas putida interactions.

Subsidie
€ 1.499.250
2024

Projectdetails

Introduction

Bacteriophages, viruses of bacteria, are the most abundant life form on Earth. The prospect of using them in the fight against pathogenic bacteria has long been recognized, but their very high specificity and unpredictable reproduction limits their use in medicine.

Background

The mechanisms phages use to fight bacteria are attractive candidates for the development of novel antimicrobial applications, but are still very poorly understood. Indirect evidence exists of toxin-antitoxin systems (TAS) and stringent response involvement in phage defense. The constant co-evolution of phages and bacteria suggests that phages have a way of overcoming all of the wide variety of bacterial defense systems. Yet, no direct phage mechanisms targeting bacterial stringent response have been identified.

Hypothesis

We hypothesize that as the bacterial toxin-antitoxin systems and stringent response play a part in the arms race between bacteria and phages, we can provide direct molecular evidence and identify phage proteins involved in these interactions by:

  1. Creating and characterizing, morphologically and molecularly, a novel library of phages infecting Pseudomonas putida PaW85.
  2. Uncovering the stringent response- and TAS-mediated phenotypic effects and their molecular mechanisms on P. putida phage tolerance.
  3. Discovering and characterizing, functionally and structurally, the anti-TAS and anti-stringent response phage effectors.
  4. Determining the toxicity and specificity of the identified phage-derived toxins by testing them on different bacterial species.

Significance

This study will bridge several gaps in the phage-bacteria interaction research, advance the research of phage-tolerant bioremediation strains, and provide crucial basic knowledge that can lead to the development of novel, efficient phage therapy solutions that target bacterial stress mechanisms.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.250
Totale projectbegroting€ 1.499.250

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TARTU ULIKOOLpenvoerder

Land(en)

Estonia

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.

€ 1.500.000
ERC Advanced...

Breaking resistance of pathogenic bacteria by chemical dysregulation

The project aims to combat antibiotic-resistant bacteria by developing innovative small molecules that dysregulate bacterial physiology through a three-tiered chemical strategy.

€ 2.499.785
ERC Consolid...

Phage infection of bacterial biofilm

This project aims to characterize the dynamics of Herelleviridae phage phi812 in Staphylococcus aureus biofilms to enhance phage therapy effectiveness against antibiotic-resistant infections.

€ 1.992.976
ERC Starting...

The evolution of host manipulation by bacteriophage.

This project aims to investigate how Regulatory Switch phages manipulate bacterial behavior, enhancing our understanding of phage-bacteria interactions and potential applications in bacterial control.

€ 2.255.511
ERC Starting...

Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs

This project aims to map bacterial antiviral immunity and discover novel anti-phage compounds, potentially transforming our understanding of prokaryotic immune systems and leading to new antiviral therapies.

€ 1.496.500

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

in silico bio-evolutio - novel AI paradigm for molecular biology

This project aims to accelerate phage therapy by using an AI platform for in silico simulations to optimize phage selection, reducing experimental time and enhancing personalized treatment effectiveness.

€ 1.692.596
EIC Accelerator

Fast, easy diagnostics for personalised phage therapy

Vésale Bioscience's Phagogram is an automated diagnostic tool that rapidly identifies effective bacteriophages for personalized phage therapy, reducing testing time from days to hours.

€ 1.800.000